FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia
(Thomson Reuters ONE) -
Novartis International AG /
FDA expands use of Novartis drug Promacta® to include treatment of children ages
1 and older with chronic immune thrombocytopenia
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* New oral suspension formulation, designed for younger children with rare
blood disorder, is now approved
* For about one in four children with ITP, the condition persists for more
than 12 months after diagnosis and is considered chronic[1],[2]
* Already approved for people 6 years of age and older with chronic ITP,
Promacta is the only oral TPO-receptor agonist that may increase platelet
production
Basel, August 24, 2015 - Novartis announced today that the US Food and Drug
Administration (FDA) has approved an expanded use for Promacta(®) (eltrombopag)
to include children 1 year of age and older with chronic immune thrombocytopenia
(ITP) who have had an insufficient response to corticosteroids, immunoglobulins
or splenectomy. The updated label also includes a new oral suspension
formulation of Promacta that is designed for younger children who may not be
able to swallow tablets. Promacta was approved by the FDA as a tablet
formulation in June 2015 for children 6 years of age and older and in 2008 for
use in adult patients with the same condition.
ITP affects as many as 5 in 100,000 children each year[3] and is characterized
by a low platelet count[4]. Chronic ITP, defined as ongoing disease more than
12 months after diagnosis[2], occurs in 13-36% of children with immune
thrombocytopenia[1]. A small number of pediatric patients with chronic ITP may
be at risk of significant bleeding[5].
"It's challenging and often very emotional for parents of a baby or toddler
affected by a rare condition to manage their child's disease with limited
treatment options," said Bruno Strigini, President, Novartis Oncology. "Today's
label expansion for Promacta provides a new disease management option for
families affected by chronic ITP and highlights our commitment to providing
treatments for even the youngest children with rare diseases."
The label expansion of Promacta was based on data from two double-blind,
placebo-controlled trials, including the largest Phase III clinical trial in
this patient population. Treatment with Promacta significantly increased and
sustained platelet counts among pediatric patients with chronic ITP with an
insufficient response to prior chronic ITP therapies, and some patients taking
concomitant ITP medications were able to reduce or discontinue their use of
these medications, primarily corticosteroids. Promacta should be used only in
those whose degree of thrombocytopenia and clinical condition increase the risk
for bleeding.
Promacta is a once-daily oral thrombopoietin (TPO) receptor agonist that works
by inducing stimulation and differentiation of megakaryocytes (large cells,
found especially in bone marrow) from bone marrow stem cells to increase
platelet production[6].
About the PETIT and PETIT2 Clinical Trials
PETIT was a Phase II, multi-center, three-part study to investigate the
efficacy, safety and tolerability of Promacta in pediatric patients (ages 1 to
17 years) with previously treated chronic ITP. Part 1 was an open label, dose
finding study; Part 2 was double-blind and placebo-controlled, and Part 3 was an
open-label extension. The primary endpoint, which was percentage of participants
who achieved a platelet count >=50 Gi/L without rescue therapy at least once
between Weeks 1 and 6, was met by 62% and 32% of Promacta and placebo patients,
respectively (p=0.011). The secondary efficacy endpoint analyses demonstrated
clinically meaningful benefit in terms of decreased need for rescue treatment
(13% of patients on Promacta compared to 50% of patients on placebo)[7].
PETIT2 was a Phase III, multi-center, two-part study to investigate the
efficacy, safety and tolerability of Promacta in pediatric patients (ages 1 to
17 years) with previously treated chronic ITP. Part 1 was randomized, double-
blind and placebo-controlled and Part 2 was an open-label extension. The primary
endpoint, which was percentage of participants who achieved a platelet count
/>=50 Gi/L without rescue therapy for at least six out of eight weeks between
Weeks 5 and 12 of Part 1 of the study, was met by 41% of patients treated with
Promacta and 3% of patients treated with placebo (p<0.001). This result was
consistent across the age cohorts. The secondary efficacy endpoint analyses
demonstrated clinically meaningful benefit in terms of decreased need for rescue
treatment (19% of patients on Promacta compared to 24% of patients on placebo)
during the randomized, double-blind period. Patients were permitted to reduce or
discontinue baseline ITP therapy only during the open-label phase of the trial.
In the open label eltrombopag-only period, 15 of 87 patients were taking
concomitant ITP medications at baseline. Of these 15 patients, 8 (53%) had a
sustained reduction or permanent discontinuation of at least one baseline ITP
medication (7 patients permanently discontinued and one patient had sustained
reduction for >=18 weeks)[8].
In both studies, safety was consistent with the known safety profile of Promacta
in chronic ITP in adults and the population under study. No new safety signals
were detected. The most common adverse reactions in pediatric chronic ITP
patients 1 year and older (greater than or equal to 10% and greater than
placebo) were upper respiratory tract infection and nasopharyngitis[7],[8].
About Chronic ITP
ITP is a blood disorder characterized by blood that does not clot as it should
due to a low number of platelets. People who have ITP often have purple bruises
or tiny red or purple dots on the skin. They also may have nosebleeds, bleeding
from the gums during dental work, or other bleeding that's hard to stop. In most
cases, an autoimmune response is thought to cause ITP in which a person's immune
system attacks and destroys its own platelets[4].
The two types of ITP are acute (temporary or short-term) and chronic (long-
lasting). Acute ITP mainly occurs in children, often after a viral infection,
and generally lasts less than 6 months. The platelet count returns to normal
within 6 to 12 months and treatment may not be needed[4]. Chronic ITP, defined
as ongoing disease more than 12 months after diagnosis[2], occurs in 13-36% of
children with immune thrombocytopenia[1]. A small number of pediatric patients
with chronic ITP may be at risk of significant bleeding[5].
The goal of treatment in chronic ITP for children is to maintain a safe platelet
count that reduces the risk of bleeding[4]. The most commonly available and used
therapies-corticosteroids and intravenous immunoglobulin (IVIG)-are associated
with side effects that are often difficult to tolerate in a pediatric
setting[5],[9],[10].
About Promacta
Promacta is marketed under the brand name Promacta(®) in the US and Revolade(®)
in most countries outside the US.
Promacta is a prescription medicine used to treat adults and children 1 year of
age and older with low blood platelet counts due to chronic immune (idiopathic)
thrombocytopenia (ITP), when other medicines to treat ITP or surgery to remove
the spleen have not worked well enough. Promacta is used to try to raise
platelet counts in order to lower the risk for bleeding. Promacta should be used
only in those whose degree of thrombocytopenia and clinical condition increase
the risk for bleeding. It is not known if Promacta is safe and effective in
children younger than 1 year with ITP. An application was submitted to the
European Medicines Agency (EMA) earlier this year to include chronic ITP
patients 1 year and older. This application includes chemistry, manufacturing
and control (CMC) data supporting the new oral suspension formulation of
Promacta.
The safety and efficacy profile of Promacta has not yet been established in
countries outside the US in pediatric patients with chronic ITP. For various
reasons, including the uncertainty of clinical trials, there is no guarantee
that Promacta will become commercially available for pediatric patients with
chronic ITP anywhere else in the world. Information about clinical trials for
chronic ITP can be obtained by healthcare professionals at
www.clinicaltrials.gov.
In addition to the approval of Promacta for chronic ITP in the US, it is
approved to treat low blood platelet counts in people with chronic hepatitis C
virus (HCV) infection before and during treatment with interferon. Promacta
should only be used in people with chronic hepatitis C whose low blood platelet
counts keep them from starting or continuing interferon-based therapy. It is not
known if Promacta is safe and effective when used with other antiviral medicines
that are approved to treat chronic hepatitis C.
Promacta is a prescription medicine used to treat people with severe aplastic
anemia (SAA) when other medicines to treat SAA have not worked well enough.
Promacta is not used to make a patient's platelet count normal.
Important Safety Information for Promacta(®) (eltrombopag)
Promacta can cause serious side effects, including liver problems, abnormal
liver function tests, high platelet counts and higher risk for blood clots, and
new or worsened cataracts (a clouding of the lens in the eye).
For patients who have chronic hepatitis C virus and take Promacta with
interferon and ribavirin treatment, Promacta may increase the risk of liver
problems. Patients should tell a healthcare provider right away if they have any
of these signs and symptoms of liver problems including yellowing of the skin or
the whites of the eyes (jaundice), unusual darkening of the urine, unusual
tiredness, right upper stomach area pain, confusion, swelling of the stomach
area (abdomen).
A healthcare provider will order blood tests to check the liver before starting
Promacta and during Promacta treatment. In some cases, treatment with Promacta
may need to be stopped due to changes in liver function tests.
The risk of getting a blood clot is increased if the platelet count is too high
during treatment with Promacta. The risk of getting a blood clot may also be
increased during treatment with Promacta if platelet counts are normal or low.
Some forms of blood clots, such as clots that travel to the lungs or that cause
heart attacks or strokes can cause severe problems or death. A healthcare
provider will check blood platelet counts, and change the dose of Promacta or
stop Promacta, if platelet counts get too high. Patients should tell a
healthcare provider right away if they have signs and symptoms of a blood clot
in the leg, such as swelling, pain, or tenderness in the leg.
People with chronic liver disease may be at risk for a type of blood clot in the
stomach area. Patients should tell a healthcare provider right away if they have
stomach area pain that may be a symptom of this type of blood clot.
New or worsened cataracts have happened in people taking Promacta. A healthcare
provider will check the patient's eyes before and during treatment with
Promacta. Patients should tell a healthcare provider about any changes in
eyesight while taking Promacta.
Patients should tell a healthcare provider about all the medicines they take,
including prescription and over-the-counter medicines, vitamins, and herbal
supplements. Promacta may affect the way certain medicines work. Certain
medicines may keep Promacta from working correctly. Patients should take
Promacta at least 2 hours before or 4 hours after taking products such as
antacids used to treat stomach ulcers or heartburn and multivitamins or products
that contain iron, calcium, aluminum, magnesium, selenium, and zinc, which may
be found in mineral supplements. Patients should ask a healthcare provider if
they are not sure if the medicine is one that is listed above.
Patients should avoid situations and medications that may increase the risk of
bleeding while taking Promacta.
The most common side effects of Promacta when used to treat chronic ITP in
adults are: nausea; diarrhea; upper respiratory tract infection (symptoms may
include runny nose, stuffy nose, and sneezing); vomiting; muscle aches; urinary
tract infection (symptoms may include frequent or urgent need to urinate, low
fever in some people, pain or burning with urination); pain or swelling
(inflammation) in the throat or mouth (oropharyngeal pain and pharyngitis);
abnormal liver function tests; back pain; flu-like symptoms (influenza),
including fever, headache, tiredness, cough, sore throat, and body aches; skin
tingling, itching, or burning; and rash.
The most common side effects of Promacta in children 1 year and older when used
to treat chronic ITP are: upper respiratory tract infections (symptoms may
include runny nose, stuffy nose, and sneezing); pain or swelling (inflammation)
in the nose and throat (nasopharyngitis); cough; diarrhea; pyrexia; runny,
stuffy nose (rhinitis); stomach (abdominal) pain; pain or swelling
(inflammation) in the throat or mouth; toothache; abnormal liver function tests;
rash; runny nose (rhinorrhea).
The most common side effects when Promacta is used in combination with other
medicines to treat chronic HCV are: low red blood cell count (anemia); fever;
tiredness; headache; nausea; diarrhea; decreased appetite; flu-like symptoms
(influenza), including fever, headache, tiredness, cough, sore throat, and body
aches; feeling weak; trouble sleeping; cough; itching; chills; muscle aches;
hair loss; and swelling in the ankles, feet, and legs.
The most common side effects of Promacta when used to treat severe aplastic
anemia are: nausea, feeling tired, cough, diarrhea, headache, pain in arms,
legs, hands or feet, shortness of breath, fever, dizziness, pain in nose or
throat, abdominal pain, bruising, muscle spasms, abnormal liver function tests,
joint pain, and runny nose.
Laboratory tests may show abnormal changes to the cells in bone marrow.
Please see full Prescribing Information, including Boxed WARNING and Medication
Guide, for Promacta(®).
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "commitment," "yet," "will," or similar terms, or by express or
implied discussions regarding potential new indications or labeling for
Promacta, new formulations of Promacta, or regarding potential future revenues
from Promacta. You should not place undue reliance on these statements. Such
forward-looking statements are based on the current beliefs and expectations of
management regarding future events, and are subject to significant known and
unknown risks and uncertainties. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those set forth in the forward-looking
statements. There can be no guarantee that Promacta will be submitted or
approved for any additional indications, labeling or formulations in any market,
or at any particular time. Nor can there be any guarantee that Promacta will be
commercially successful in the future. In particular, management's expectations
regarding Promacta could be affected by, among other things, the uncertainties
inherent in research and development, including unexpected clinical trial
results and additional analysis of existing clinical data; unexpected regulatory
actions or delays or government regulation generally; the company's ability to
obtain or maintain proprietary intellectual property protection; general
economic and industry conditions; global trends toward health care cost
containment, including ongoing pricing pressures; unexpected safety issues;
unexpected manufacturing issues, and other risks and factors referred to in
Novartis AG's current Form 20-F on file with the US Securities and Exchange
Commission. Novartis is providing the information in this press release as of
this date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2014, the Group achieved net
sales of USD 58.0 billion, while R&D throughout the Group amounted to
approximately USD 9.9 billion (USD 9.6 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 120,000
full-time-equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
References
[1] George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a
practice guideline developed by explicit methods for the American Society of
Hematology. Blood. 1996;88(1):3-40.
[2] Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology,
definitions and outcome criteria in immune thrombocytopenic purpura of adults
and children: report from an international working group. Blood.
2009;12;113(11):2386-2393.
[3] Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura.
Curr Opin Hematol. 2007;14(5):515-519.
[4] Immune Thrombocytopenia. US National Institutes of Health website.
http://www.nhlbi.nih.gov/book/export/html/4917. Accessed August 5, 2015.
[5] Neunert C, Lim W, Crowther M, et al. The American Society of Hematology
2011 evidence-based practice guideline for immune thrombocytopenia. Blood.
2011;117(16):4190-4207.
[6] Full Prescribing Information.
[7] Bussel JB, Garcia de Miguel P, Despotovic JM, et al. Eltrombopag for the
treatment of children with persistent and chronic immune thrombocytopenia
(PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol.
2015; published online July 29, 2015.
[8] Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for
children with chronic immune thrombocytopenia (PETIT2): a randomised,
multicentre, placebo-controlled trial. Lancet. 2015; published online July
29, 2015.
[9] Provan D, Stasi R, Newland AC, et al. International consensus report on the
investigation and management of primary immune thrombocytopenia. Blood.
2010;115(2):168-186.
[10] Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med.
2002;346(13):995-1008.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Nicole Riley
Novartis Global Media Relations Novartis Oncology
+41 61 324 7999 (direct) +1 862 778 3110 (direct)
+41 79 593 4202 (mobile) +1 862 926 9040 (mobile)
eric.althoff(at)novartis.com nicole.riley(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448
Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1947261/707012.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#1947261]
Unternehmensinformation / Kurzprofil:
Datum: 24.08.2015 - 18:08 Uhr
Sprache: Deutsch
News-ID 415535
Anzahl Zeichen: 23404
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 187 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
